Parkinson’s Disease and Zoledronic Acid (TOPAZ) Study
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: Yes
The purpose of the TOPAZ study is to determine whether zoledronic acid, an approved bone strengthening medication for osteoporosis, can prevent fractures and decrease the risk of dying in people with Parkinson’s disease and other parkinsonism. The information learned in this study will help doctors understand whether they should treat their patients with PD with zoledronic acid.
Who Can Participate
Participants 60 years of age and older with Parksinson’s disease or another form of parkinsonism who have not had a hip fracture may be eligible for this study.